Dementia With Lewy Bodies Clinical Trial
Official title:
Imaging Inflammation in Patients With Diffuse Lewy Body Disease
Verified date | October 2019 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study uses a special type of scan called a positron emission tomography (PET) scan to
take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected
into the body.
11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study
is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia
or dementia with Lewy bodies.
11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a
treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the
brain.
Status | Completed |
Enrollment | 5 |
Est. completion date | September 4, 2019 |
Est. primary completion date | September 4, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Inclusion criteria for patients: 1. Age 60 and older. 2. Meet criteria for either a) dementia with Lewy bodies, or b) Parkinson's disease dementia. 3. Written and oral fluency in English. 4. Able to participate in all scheduled evaluations and to complete all required tests and procedures. 5. In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study. - Inclusion criteria for controls: 1. Age 60 and older. 2. Normal cognitive and motor function based on neurological examination. 3. Written and oral fluency in English. 4. Able to participate in all scheduled evaluations and to complete all required tests and procedures. 5. In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study. Exclusion Criteria: 1. Past or present history of certain other brain disorders. 2. Certain significant medical conditions. Examples are uncontrolled epilepsy or multiple serious injuries. 3. Contraindication to MRI scanning. 4. Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.). 5. Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits. 6. Low affinity binding on TSPO genetic screen 7. Currently taking anticoagulant drugs (e.g., warfarin). 8. Women of childbearing potential. |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
William Charles Kreisl | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma) | 1 year | ||
Secondary | Relative 11C-PBR28 binding | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03996460 -
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
|
Phase 2 | |
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Active, not recruiting |
NCT01208675 -
The Swedish BioFINDER Study
|
||
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Recruiting |
NCT03672448 -
The China Longitudinal Aging Study of Cognitive Impairment
|
||
Completed |
NCT01340001 -
Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies
|
N/A | |
Not yet recruiting |
NCT04760860 -
Terazosin for Dementia With Lewy Bodies
|
Phase 1/Phase 2 | |
Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
Terminated |
NCT02928445 -
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
|
Phase 2/Phase 3 | |
Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
Completed |
NCT05188105 -
Alpha tACS in Dementia With Lewy Bodies
|
N/A | |
Active, not recruiting |
NCT04167813 -
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
|
Phase 2 | |
Enrolling by invitation |
NCT04954183 -
Development of an EEG Diagnostic for Alzheimer's Disease
|
||
Recruiting |
NCT05326750 -
Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases
|
N/A | |
Completed |
NCT01023672 -
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
|
Phase 4 | |
Completed |
NCT03907748 -
Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia
|
N/A | |
Completed |
NCT04649164 -
Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
|
N/A | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Completed |
NCT05885620 -
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia
|
N/A |